TransMed Research has been set up to join excellence in research with a market-oriented approach.
Our purpose is to shorten the translational process and the timing for the design and development of new products offering innovative, flexible and efficient methodologies and services based on high-throughput analysis for animal behavior, cell-based assays and clinical biomarkers.
TransMed Research supports all types of in vitro and in vivo studies, from preliminary non-GLP toxicology and efficacy studies to formal GLP studies. TransMed Research supplies studies and tests ready to be included in the applications to regulatory agencies like AIFA (Italian Pharma Agency), EMA (European Medicine Agency) and FDA (Food and Drug Administration) to be authorized to market pharmaceutical products.
TransMed Research is a partner for public health authorities, private health care and insurance companies, to study risk factors related to the lifestyle and comorbidities, and propose best practices and guidelines. TransMed Research is also an experienced partner for grant applications at the national and international level.